GSK's Bepirovirsen Achieves Milestone in Hepatitis B Trials
GSK announced that its experimental drug bepirovirsen met primary endpoints in two clinical studies for hepatitis B. This success supports the company's regulatory filing plans and aims to contribute significantly to its revenue goals.
Insights:
GSK plc has announced a significant breakthrough with its experimental hepatitis B drug, bepirovirsen, which has successfully met the primary endpoints in two pivotal clinical studies. The trials demonstrated statistically significant and clinically meaningful functional cure rates, positioning GSK to file for regulatory approval in the first quarter of 2026. This development marks an early success for the company's new CEO, Luke Miels luke miels, who took over from Emma Walmsley emma walmsleyat the start of the year.
